Two redundant transcription factor binding sites in a single enhancer are essential for mammalian sex determination. 2024

Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
The Mina and Everard Goodman Faculty of Life Sciences and the Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat GanĀ 5290002, Israel.

Male development in mammals depends on the activity of the two SOX gene: Sry and Sox9, in the embryonic testis. As deletion of Enhancer 13 (Enh13) of the Sox9 gene results in XY male-to-female sex reversal, we explored the critical elements necessary for its function and hence, for testis and male development. Here, we demonstrate that while microdeletions of individual transcription factor binding sites (TFBS) in Enh13 lead to normal testicular development, combined microdeletions of just two SRY/SOX binding motifs can alone fully abolish Enh13 activity leading to XY male-to-female sex reversal. This suggests that for proper male development to occur, these few nucleotides of non-coding DNA must be intact. Interestingly, we show that depending on the nature of these TFBS mutations, dramatically different phenotypic outcomes can occur, providing a molecular explanation for the distinct clinical outcomes observed in patients harboring different variants in the same enhancer.

UI MeSH Term Description Entries

Related Publications

Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
June 1992, Journal of virology,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
December 2013, Philosophical transactions of the Royal Society of London. Series B, Biological sciences,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
February 2009, Nucleic acids research,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
November 2012, Genetics,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
January 2012, BMC bioinformatics,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
June 2017, Scientific reports,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
February 2006, Theoretical biology & medical modelling,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
February 2024, Human genomics,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
December 2006, Genome research,
Meshi Ridnik, and Elisheva Abberbock, and Veronica Alipov, and Shelly Ziv Lhermann, and Shoham Kaufman, and Maor Lubman, and Francis Poulat, and Nitzan Gonen
July 2014, Nature communications,
Copied contents to your clipboard!